Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...

One is that investors are going to continue to look for opportunities where generative AI or just the requirements to supply ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Insulin has long been the typical pharmacological go-to agent for gestational diabetes, the researchers pointed out, but oral ...

Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform.Don't Miss Our New Year's Offers:Discover the latest stocks ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, and the availability of approved alternatives.

Orbis emerged from stealth in February 2024 with $28.1 million in seed funding. The Danish biotech, which aims to flip ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Novo Nordisk (NYSE: NVO) has sparked investor interest primarily because of its weight loss treatments. Where to invest ...

AIMRC & WECARE will host Juleen Zierath of the Karolinska Institute, Stockholm, at 12:55 p.m. Wednesday, Jan. 15, at the Jones Family Student-Athlete Success Center, room 104.